Clinical trialNCT05501704RecruitingPhase 2Interventional

ETHAN - ET for Male BC

SponsorJose Pablo LeoneEnrollment60Hormone Receptor Negative Breast CarcinomaHormone Receptor-positive Breast CancerMale Breast Cancer

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This research study is looking to see how well male breast cancer responds to preoperative treatment with endocrine therapy and which endocrine therapy regimen is the most effective treatment for male breast cancer. The drugs used in this study are: * Tamoxifen * Anastrozole * Degarelix * Abemaciclib

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Jose Pablo Leone, MD
Dana-Farber Cancer Institute
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Georgetown University Medical Center
Washington D.C., District of Columbia, United States
Elaine Walsh, MD
Recruiting
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Jose Pablo Leone, MD
Recruiting
Mayo Clinic
Rochester, Minnesota, United States
Kathryn Ruddy, MD
Recruiting
Unc Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, United States
Yara Abdou, MD
Recruiting
University of Pennsylvania, Abramson Cancer Center
Philadelphia, Pennsylvania, United States
Igor Makhlin, MD
Recruiting
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania, United States
Priscilla McAuliffe, MD
Recruiting
Vanderbilt Cancer Center
Nashville, Tennessee, United States
Jessica Sharpe, MD
Recruiting
M. D. Anderson Cancer Center at University of Texas
Houston, Texas, United States
Jasmine Sukumar, M.D
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Abemaciclib →Anastrozole →Degarelix →Tamoxifen →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 11 Oct 2023
Primary completion: 1 Apr 2027
Completion: 1 Apr 2036
Last update posted: 30 Apr 2026
Registered enrollment: 60
Registry id: NCT05501704

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.